Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6114148 | Transfusion and Apheresis Science | 2014 | 6 Pages |
Abstract
Starting in 2013, blood donors must be tested at least using: (1) one monoclonal anti-D and one anti-CDE (alternatively full RhCcEe phenotyping), and (2) all RhD negative donors must be tested for RHD exons 5 and 10 plus one further exonic, or intronic RHD specificity, according to the guidelines of the Blood Transfusion Service of the Swiss Red Cross (BTS SRC). In 2012 an adequate stock of RHD screened donors was built. Of all 25,370 RhD negative Swiss donors tested in 2012, 20,015 tested at BTS Berne and 5355 at BTS Zürich, showed 120 (0.47%) RHD positivity. Thirty-seven (0.15%) had to be redefined as RhD positive. Routine molecular RHD screening is reliable, rapid and cost-effective and provides safer RBC units in Switzerland.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Sofia Lejon Crottet, Christine Henny, Stefan Meyer, Franziska Still, Martin Stolz, Jochen Gottschalk, Kathrin Neuenschwander, Behrouz Mansouri Taleghani, Peter Gowland, Beat M. Frey, Stefano Fontana, Hein Hustinx, Christoph Niederhauser,